Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Talpaz

Showing results (71-80 of 350) with videos related to

Pageof 35
Sort By:
Bailliere'S Clinical Haematology|June 1, 1997
The M.D. Anderson Cancer Center experience with interferon-alpha therapy in chronic myelogenous leukaemiaM Talpaz, H M Kantarjian, S O'Brien, et al.
Blood|May 30, 1998
Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemiaS Faderl, H M Kantarjian, M Talpaz, et al.
International Journal of Oncology|November 18, 2000
Clinical significance of minimal residual disease in leukemiaS Faderl, H M Kantarjian, M Talpaz, et al.
Cancer Investigation|January 1, 1989
Therapy of chronic myelogenous leukemia with interferonR Kurzrock, J U Gutterman, H Kantarjian, et al.
American Journal of Clinical Oncology|January 1, 1991
Cytokines in tumor therapy. Interleukin-3R Kurzrock, Z Estrov, M Talpaz, et al.
Annals of Internal Medicine|July 31, 1999
Chronic myelogenous leukemia: biology and therapyS Faderl, M Talpaz, Z Estrov, et al.
Blood|April 27, 1999
Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?S Faderl, M Talpaz, H M Kantarjian, et al.
Experimental Hematology|September 1, 1995
Role of suramin as an IL-1 inhibitor in suppression of acute myelogenous leukemia progenitor proliferationZ Estrov, M Talpaz, E H Estey, et al.
Seminars in Oncology|October 26, 2000
New treatment approaches for chronic myelogenous leukemiaS Faderl, H M Kantarjian, M Talpaz, et al.
Bone Marrow Transplantation|January 1, 1989
Clinical studies with interferons in Philadelphia positive chronic myelogenous leukemiaM Talpaz, H Kantarjian, R Kurzrock, et al.
Pageof 35

Showing results (71-80 of 350) with videos related to

Sort By:
Pageof 35
Bailliere'S Clinical Haematology|June 1, 1997
The M.D. Anderson Cancer Center experience with interferon-alpha therapy in chronic myelogenous leukaemiaM Talpaz, H M Kantarjian, S O'Brien, et al.
Blood|May 30, 1998
Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemiaS Faderl, H M Kantarjian, M Talpaz, et al.
International Journal of Oncology|November 18, 2000
Clinical significance of minimal residual disease in leukemiaS Faderl, H M Kantarjian, M Talpaz, et al.
Cancer Investigation|January 1, 1989
Therapy of chronic myelogenous leukemia with interferonR Kurzrock, J U Gutterman, H Kantarjian, et al.
American Journal of Clinical Oncology|January 1, 1991
Cytokines in tumor therapy. Interleukin-3R Kurzrock, Z Estrov, M Talpaz, et al.
Annals of Internal Medicine|July 31, 1999
Chronic myelogenous leukemia: biology and therapyS Faderl, M Talpaz, Z Estrov, et al.
Blood|April 27, 1999
Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?S Faderl, M Talpaz, H M Kantarjian, et al.
Experimental Hematology|September 1, 1995
Role of suramin as an IL-1 inhibitor in suppression of acute myelogenous leukemia progenitor proliferationZ Estrov, M Talpaz, E H Estey, et al.
Seminars in Oncology|October 26, 2000
New treatment approaches for chronic myelogenous leukemiaS Faderl, H M Kantarjian, M Talpaz, et al.
Bone Marrow Transplantation|January 1, 1989
Clinical studies with interferons in Philadelphia positive chronic myelogenous leukemiaM Talpaz, H Kantarjian, R Kurzrock, et al.
Pageof 35